|Bid||89.00 x 800|
|Ask||113.65 x 800|
|Day's Range||110.11 - 111.31|
|52 Week Range||98.34 - 130.29|
|PE Ratio (TTM)||72.03|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||121.57|
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena ...
Far more tame were stock charts of GGP (NYSE:GGP), Alaska Air Group (NYSE:ALK) and Varian Medical Systems (NYSE:VAR), which are heading into Tuesday’s action as a trader’s top prospects — largely because they didn’t dish out tricky, unfounded volatility. Both are trends that retail space landlord GGP benefit from. • There’s a likely resistance line at $23.85, where VAR bumped into a technical ceiling late last year and early this year.
Monday saw a heavy slate of M&A announcements. Here are some of the most significant involving publicly traded companies: Amcor Limited will purchase Bemis Company, Inc. (NYSE: BMS ) in a $6.8 billion ...
Acquisition expands Varian's motion-management portfolio and presence in Germany PALO ALTO, Calif. , Aug. 6, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced the acquisition of privately-held humediQ ...
On August 3, ViewRay (VRAY) reported revenues of $16.4 million for the second quarter of 2018, which is a YoY (year-over-year) rise of 2,248.6%. The performance was driven by the recognition of revenues related to the sale of three MRIdian Linacs for MRI-guided radiation therapy. It also received new orders worth $34.6 million for its MRIdian systems. At the end of the quarter, it had a backlog of orders worth $200 million, which is a YoY rise of 11.1%.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Hologic (HOLX), a leading women’s health technology player, will release its fiscal third-quarter earnings results on July 31 after markets close. The stock fell more than 9% following the results. Many analysts covering Hologic cut their target prices on HOLX stock in the following days. As of July 30, Reuters reported that of the 19 analysts covering Hologic, ~63% have a “buy” or “strong buy” rating on HOLX stock.
Varian Medical Systems (VAR) reported its fiscal Q3 2018 results on July 25. Net sales surged 12% YoY (year-over-year) from $632.8 million to $709.1 million.
Baxter International (BAX) released its Q2 2018 results on July 26. During the quarter, Baxter expanded its medication delivery portfolio with two new infusion pumps. Baxter International’s marketing and administrative expenses increased 8% from $630 million in Q2 2017 to $681 million in Q2 2018, and its research and development expenses increased by 12% from $155 million in Q2 2017 to $174 million in Q2 2018.
Third Quarter 2018 Summary − Revenues of $709 million grew 12 percent, or 10 percent in constant currency − Oncology gross orders grew 11 percent, or 9 percent in constant currency − GAAP operating earnings ...
NEW YORK, NY / ACCESSWIRE / July 25, 2018 / Varian Medical Systems, Inc. (NYSE: VAR) will be discussing their earnings results in their Q3 Earnings Call to be held on July 25, 2018 at 5:00 PM Eastern Time. ...
Varian Medical Systems (VAR) is expected to incur SG&A (selling, general, and administrative) expenses of $120.88 million in Q3 2018 compared to $55.1 million in Q3 2017, an increase of more than 100%. The company’s R&D (research and development) expenses are expected to increase 0.94%, from $55 million in Q3 2017 to $55.6 million in Q3 2018. Its total operating expenses are expected to increase 0.97%, from $171.8 million in Q3 2017 to $173.48 million in Q3 2018.
Varian Medical Systems (VAR) is expected to report its fiscal Q3 2018 earnings on July 25. In this series, we’ll be taking a look at its expected top line and its operational and bottom-line performances for the third fiscal quarter. Varian is engaged in the design, manufacture, and commercialization of hardware and software products for the treatment of cancer with radiotherapy, stereotactic radiosurgery, brachytherapy, and stereotactic body radiotherapy.
The Medical product market further gains momentum on the back of a recent two-year suspension of the controversial 2.3% Medical Device tax.
PALO ALTO, Calif. , July 24, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it will be showcasing its advanced cancer care solutions including a new version of Eclipse ™ treatment planning software ...
July 13 (Reuters) - Sirtex Medical Ltd: * PAYMENT OF A$15.8 MILLION BREAK FEE TO VARIAN * CONFIRMS HAS RECEIVED CASH REIMBURSEMENT FROM CDH-CGP EQUIVALENT TO AMOUNT PAID TO VARIAN Source text for Eikon: ...
Solid prospects in the Oncology segment is likely to boost Varian Medical's (VAR) top-line performance in the third quarter of fiscal 2018.
Businesses are bracing for disruptions in sales and supply chains as the U.S. and China hurtle toward levying tit-for-tat tariffs on billions of dollars in automotive products, farm crops and other goods. The U.S. imposed tariffs on $34 billion worth of imported Chinese machinery, auto parts and medical devices at 12:01 a.m. Eastern time Friday. China said it is prepared to respond immediately with equivalent tariffs on U.S. products including soybeans and sport-utility vehicles.
An Australian regulator has approved the sale of Sirtex Medical to CDH Investments and China Grand Pharmaceutical and Healthcare Holdings.
Here we analyze the major factors that have been plaguing Varian Medical (VAR) and discuss the prospects that ensure near-term recovery.